Search results
Showing 121 to 135 of 185 results for prostate cancer
Discontinued Reference number: GID-TA10465
Discontinued Reference number: GID-TA10635
In development Reference number: GID-TA11657 Expected publication date: 07 April 2027
Discontinued Reference number: GID-TAG396
Discontinued Reference number: GID-TA11177
In development Reference number: GID-TA10696 Expected publication date: TBC
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Discontinued Reference number: GID-TA10929
In development Reference number: GID-TA11163 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .